Eric Lefkofsky Tempus Pharmaceutical Firm
Tempus is a company dedicated to using machine learning and genomic sequencing to dissect an understanding of cancer tumors. Tempus has successfully raised $300 million dollars last year. This brings their combined financing of $1 billion leading to a valuation of $8.1 billion. Tempus has also decided to focus on mental health, cardiology, diabetes and infectious disease such as COVID-19. Eric Lefkofsky graduated from the University of Michigan and then the University of Michigan Law School with a Juris Doctor. All this funding will help Tempus work on diabetes, depression, and cardiology.
Machine learning is defined as automated analytical model building as a subcategory of artificial intelligence where a system is built in order to learn from the data it gathers while finding patterns leading to decisions the AI makes for us. The investor has a net worth of $1.7 billion according to Forbes even when Tempus itself does not need capital. The best companies start off as a solution to a major problem in the entrepreneur’s life such as in Eric Lefkofksy´s case.
It is the goal of the Tempus Firm platform to collect data from patient charts, which remains disorganized in existing electronic record situations. Tempus pharmaceutical firm has invented a way to match cancer patients with clinical trials. Tempus was originally founded in Chicago, a city where having a start-up is a hard situation but now employs more than 1,000 people. With a focus on deadly disease, Lefkofsky is trying to raise money for tempus, such as $200 billion with Google’s participation to invest in Tempus recently.